US-based medical technology firm Becton, Dickinson and Company (BD) has completed the acquisition of CareFusion for around $12.2bn.
The deal was first announced in October 2014 and received European Commission approval this month.
As part of the deal, BD has paid $58.00 per share in cash and stock to the shareholders of San Diego-based biomedical equipment maker.
Under the terms of the deal, CareFusion shareholders received $49.00 in cash and 0.0777 of a share of BD for each share of CareFusion and allowed the company to become a wholly-owned subsidiary of BD.
BD chairman, CEO and president Vincent Forlenza said: "We are very excited to announce the consummation of the CareFusion acquisition, as it represents a major milestone in BD’s 118-year history.
"We look forward to the future with confidence as we become one of the largest global leaders in medical technology, and are better positioned to partner with healthcare providers around the world to provide safer, more economical and improved care."
Serving the health care industry, CareFusion produces Alaris infusion pumps and IV sets, MaxPlus and MaxZero IV connectors and sets, Pyxis automated dispensing and patient identification systems.
The company also manufactures AVEA, LTV series and AirLife ventilation and respiratory products, ChloraPrep products, MedMined services for data mining surveillance, V. Mueller surgical instruments, in addition to products that support interventional medicine.
Image: BD has acquired San Diego-based biomedical equipment maker, CareFusion. Photo: courtesy of stockimages/ FreeDigitalPhotos.net.